Epidemiology, Management, and Follow-up of Patients with Selective IgA Deficiency: Current Evidence and Clinical Considerations Immunology

Management is primarily preventive and supportive. For patients with recurrent infections, prompt targeted antibiotic treatment and consideration of prophylactic antibiotics are central; aggressive evaluation for specific antibody responses (e.g., to pneumococcal vaccines) and assessment of IgG subclass or other humoral defects is recommended when infections are frequent or severe. Routine immunoglobulin replacement therapy (IgRT/IVIG) is not standard for isolated SIgAD because benefits are unproven and IVIG products contain variable IgA that can rarely trigger anti-IgA-mediated reactions; IgRT may be considered only in exceptional cases (e.g., severe recurrent infections with concurrent IgG dysfunction) after specialist consultation. Follow-up should be individualized: asymptomatic patients often need only periodic clinical review and education about infection recognition and transfusion/anaphylaxis risks, whereas symptomatic patients require longitudinal surveillance for infections, development of autoimmune disease (notably celiac disease), allergy control, and periodic re-measurement of immunoglobulins since partial deficits can evolve. Vaccination (inactivated vaccines, assessment of vaccine responses) and involvement of clinical immunology for complex cases are recommended. Emerging research explores mucosal/therapeutic IgA strategies and refines indications for IgRT, but current practice emphasizes monitoring, infection control, and management of comorbid conditions.